HeimHELP • NASDAQ
add
Cybin Inc
Við síðustu lokun
7,61 $
Dagbil
7,22 $ - 8,10 $
Árabil
5,76 $ - 8,97 $
Meðalmagn
520,82 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CAD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 33,24 m. | 31,95% |
Nettótekjur | -30,58 m. | -43,25% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | -1,46 | -92,11% |
EBITDA | -33,19 m. | -32,03% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CAD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 135,02 m. | -35,39% |
Heildareignir | 258,62 m. | -14,37% |
Heildarskuldir | 21,42 m. | 112,14% |
Eigið fé alls | 237,20 m. | — |
Útistandandi hlutabréf | 23,03 m. | — |
Eiginfjárgengi | 0,69 | — |
Arðsemi eigna | -32,45% | — |
Ávöxtun eigin fjár | -34,81% | — |
Peningaflæði
Breyting á handbæru fé
| (CAD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -30,58 m. | -43,25% |
Handbært fé frá rekstri | -21,11 m. | -1,96% |
Reiðufé frá fjárfestingum | -1,08 m. | -404,19% |
Reiðufé frá fjármögnun | 20,98 m. | -89,01% |
Breyting á handbæru fé | -1,27 m. | -100,75% |
Frjálst peningaflæði | -11,14 m. | 12,30% |
Um
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Stofnsett
2019
Höfuðstöðvar
Vefsvæði
Starfsfólk
50
